Eurazeo, an investment company, agreed to invest in Kurma Partners, a French venture capital firm specializing in biotechnology and medical innovation. Financial terms were not disclosed. "With this strategic acquisition, Eurazeo reaffirms its ambition to become one of the European leaders in the financing of health care companies at all growth stages. Eurazeo is proud to be accompanying the teams at Kurma Partners, whose strong track record attests to their deep level of expertise and knowledge, positioning the firm as one of the most credible players to support the development of the most promising biotech companies in Europe," Virginie Morgon, Eurazeo CEO.